Table 3.
The table shows the comparison in absolute numbers of different pathologies investigated between the pre-COVID period and the COVID period. LGG: Low-grade glioma; HP: hypothalamic-pituitary lesion.
| Pathology | Number | % |
|---|---|---|
| HGG first diagnosis | 1550 | 26% |
| HGG first diagnosis COVID period | 1415 | 27% |
| HGG recurrence | 302 | 5% |
| HGG recurrence COVID period | 258 | 5% |
| LGG first diagnosis | 246 | 4% |
| LGG first diagnosis COVID period | 255 | 5% |
| LGG recurrence | 81 | 1% |
| LGG recurrence COVID period | 71 | 1% |
| Cranial meningiomas | 1447 | 24% |
| Cranial meningiomas COVID period | 1187 | 23% |
| Spinal meningiomas | 174 | 3% |
| Spinal meningiomas COVID period | 123 | 2% |
| Meningioma recurrence (cranial e spinal) | 118 | 2% |
| Meningioma recurrence (cranial e spinal) COVID period | 112 | 2% |
| Cranial metastasis | 607 | 10% |
| Cranial metastasis COVID period | 644 | 12% |
| Spinal metastasis | 288 | 5% |
| Spinal metastasis COVID period | 261 | 5% |
| HP lesions | 696 | 12% |
| HP lesions COVID period | 528 | 10% |
| HP recurrence | 72 | 1% |
| HP recurrence COVID period | 63 | 1% |
| CNS lymphoma | 136 | 2% |
| CNS lymphoma COVID period | 135 | 3% |
| Acoustic schwannoma | 218 | 4% |
| Acoustic schwannoma COVID period | 178 | 3% |
| Total pre-COVID | 5935 | |
| Total COVID period | 5230 |